Novavax COVID-19 Vaccine Approved In Japan, Triggers Milestone Payment From Partner Takeda

2025-09-04 09:00:37

(MENAFN- AsiaNet News)

Novavax, Inc. (NVAX) announced on Thursday that its COVID-19 vaccine, Nuvaxovid, has been approved in Japan, triggering a milestone payment from Japanese pharmaceutical company Takeda.

The vaccine was approved for initial immunization (first and second vaccinations) in individuals aged six years or older, and as a booster immunization (following the third vaccination) in individuals aged 12 years or older in the country.

Under Novavax's deal with Takeda, the company is also eligible to receive royalties on net sales of Nuvaxovid from Takeda in this vaccination season.

Get updates to this developing story <directly on Stocktwits<.

MENAFN04092025007385015968ID1110017324

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.